Meeting
2019 Gastrointestinal Cancers Symposium
Evaluation of intratumoral T cells in biopsies from advanced gastric cancer patients treated with andecaliximab and nivolumab.
Authors
Carrie Brachmann
Gilead Sciences, Inc., Foster City, CA
Carrie Brachmann , Yafeng Zhang , Emon Elboudwarej , Scott Turner , Dung Thai , Pankaj Bhargava , Jean-Philippe Metges , David Cunningham , Daniel V.T. Catenacci , Eric Van Cutsem , Zev A. Wainberg , Manish A. Shah
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Cancers of the Esophagus and Stomach
Track
Cancers of the Esophagus and Stomach
Sub Track
Multidisciplinary Treatment
Clinical Trial Registration Number
NCT02864381
Citation
J Clin Oncol 37, 2019 (suppl 4; abstr 118)
DOI
10.1200/JCO.2019.37.4_suppl.118
Abstract #
118
Poster Bd #
K10
Abstract Disclosures
Similar Posters
Poster
2019 Gastrointestinal Cancers Symposium
Exploratory evaluation of baseline tumor biomarkers and their association with response and survival in patients with previously treated advanced gastric cancer treated with andecaliximab combined with nivolumab versus nivolumab.
First Author: Jean-Philippe Metges
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Nivolumab (NIVO) + chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): 4 year (yr) follow-up of CheckMate 649.
First Author: Kohei Shitara
Poster
2024 ASCO Gastrointestinal Cancers Symposium
First-line (1L) nivolumab (NIVO) plus chemotherapy (chemo) vs chemo in patients (pts) with advanced gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma (GC/GEJC/EAC): CheckMate 649 Chinese subgroup analysis 4-year (yr) follow-up.
First Author: Lin Shen
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Efficacy and safety of nivolumab and CapeOX in patients with previously untreated FGFR2-positive, PD-L1-positive advanced gastric cancer: A single-arm, multicenter, phase 2 study NIVOFGFR2.
First Author: Ilya Tsimafeyeu